Investors & Media

Press Releases

Date Title View
Toggle Summary SAGE Therapeutics Announces Participation in February Conferences
CAMBRIDGE, Mass. , Jan. 28, 2015 (GLOBE NEWSWIRE) -- SAGE Therapeutics (Nasdaq:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-threatening, rare central nervous system (CNS) disorders, today announced management will participate in three upcoming
View HTML
Toggle Summary SAGE Therapeutics Initiates Phase 2a Trial of SAGE-547 in Postpartum Depression
CAMBRIDGE, Mass. , Jan. 12, 2015 (GLOBE NEWSWIRE) -- SAGE Therapeutics (Nasdaq:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-threatening, rare central nervous system (CNS) disorders, today announced dose administration of the first patient in a Phase 2a
View HTML
Toggle Summary SAGE Therapeutics Reports Updated Data From Ongoing Clinical Trial and Emergency Use Program of SAGE-547 in Patients With Super-Refractory Status Epilepticus
Greater Than 70 Percent Response Rate Observed in Two Patient Groups Data Reinforce Clinical Activity and Safety Profile Demonstrated by SAGE-547 Phase 3 Pivotal Trial Expected to Begin by Mid-2015 CAMBRIDGE, Mass. , Jan. 9, 2015 (GLOBE NEWSWIRE) -- SAGE Therapeutics (Nasdaq:SAGE), a clinical-stage
View HTML
Toggle Summary SAGE Therapeutics to Present at 33rd Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass. , Jan. 5, 2015 (GLOBE NEWSWIRE) -- SAGE Therapeutics (Nasdaq:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-threatening, rare central nervous system (CNS) disorders, today announced that Jeffrey Jonas , M.D., chief executive officer, is
View HTML
Toggle Summary SAGE Therapeutics Added to NASDAQ Biotechnology Index
CAMBRIDGE, Mass. , Dec. 17, 2014 (GLOBE NEWSWIRE) -- SAGE Therapeutics (Nasdaq:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-threatening, rare central nervous system (CNS) disorders, today announced that the company has been selected for addition to the
View HTML
Toggle Summary SAGE Therapeutics Reports Third Quarter 2014 Results
SAGE-547 Phase 1/2 Study Meets Primary Efficacy and Safety Endpoints
View HTML
Toggle Summary SAGE Therapeutics Reports Positive Top-Line Phase 2 Data of SAGE-547 in Patients With Super-Refractory Status Epilepticus
SAGE-547 Met Primary and Secondary Efficacy and Safety Endpoint Targets Overall Response Rate of 73 Percent Reported with No Drug-Related SAEs CAMBRIDGE, Mass. , Nov. 10, 2014 (GLOBE NEWSWIRE) -- SAGE Therapeutics (Nasdaq:SAGE) today announced that in a Phase 1/2 clinical trial of SAGE-547, an
View HTML
Toggle Summary SAGE Therapeutics Announces Six Scientific Presentations at Neuroscience 2014, the Society for Neuroscience's 44th Annual Meeting
CAMBRIDGE, Mass. , Nov. 7, 2014 (GLOBE NEWSWIRE) -- SAGE Therapeutics (Nasdaq:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-threatening, rare central nervous system (CNS) disorders, today announced that six abstracts have been accepted for poster
View HTML
Toggle Summary SAGE to Present at Credit Suisse 23rd Annual Healthcare Conference
CAMBRIDGE, Mass. , Nov. 5, 2014 (GLOBE NEWSWIRE) -- SAGE Therapeutics (Nasdaq:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-threatening, rare central nervous system (CNS) disorders, today announced that Jeffrey Jonas , M.D., chief executive officer of
View HTML
Toggle Summary First Evaluation of SAGE-547 to Treat Super-Refractory Status Epilepticus in Children Published in Annals of Neurology
Use of SAGE-547 Resolved Status Epilepticus With No Serious Adverse Events
View HTML